In Suriname, *Biomphalaria glabrata* is present in the brackish, swampy, calcium-rich waters of the northern coast, where the majority of the country’s population resides. This strip of land is the only region in the country in which *S. mansoni* is endemic. Conversion of swamps to rice paddies in the region has increased transmission [1]. The first identification of *B. glabrata* in Suriname came in a paper from 1859. The snail is likely endemic to the country rather than imported [2]. In 1911, the first schistosomiasis case was discovered in the country [3]. A survey of multiple coastal plain localities suggested mean prevalence of 12.7% in 1956 [1]. A house-to-house survey in the Saramacca district of Suriname from 1961-1964 showed 23.1% prevalence in 9456 people surveyed [4]. An estimated 9300 Surinamese were infected and 100,000 at risk out of a total population of 322,000 in 1968 [5] and an estimated 8,608 people were ‘exposed’ in 1971 [6].

The WHO reports no treatment required in 2013.
A 1972 paper detailed the treatment of 216 patients with hycanthone, and reported 213 of them cured, though with significant side effects [7]. In 1974, rates as high as 45% were reported in the Saramacca region of Suriname [3]. 1974 marked the initiation of a schistosomiasis control project in Saramacca with the overall objective of reducing prevalence to 5% [8]. To do so, the governments of Suriname and the Netherlands (which funded the project) planned to test every inhabitant, treat those infected (presumably with oxamnique), and provide other control activities like spraying snails, educating people about schistosomiasis, installing improved latrines, and ensuring proper drainage of standing water and swamps [9]. In 1976, Suriname employed 20 people for schistosomiasis control and also molluscicided 60 km [2] of land throughout the year [6]. Phase 1 of the program lasted from 1974 until 1983, when control was transferred to local authorities and integrated with existing public health programs [8]. A ‘pronounced’ regression in prevalence was seen throughout the 1970s [1].

The transition from oxamnique to praziquantel in treating schistosomiasis in 1983 [10]. In 1986, about 3,400 were infected and 34,000 people were at risk in Suriname [11]. In 1995 about 3,700 were infected and 37,000 at risk in Suriname [12]. School surveys in coastal provinces from 1997 to 2001 found between 0.3% and 4.7% prevalence [13]. Countrywide prevalence rose from 0.9% to 1.0% between 2003 and 2010 [14]. There were about 3,935 cases in Suriname in 2008 [15]. There was no record of schistosomiasis control in Suriname by 2007 [13]. The results from a 2011 survey of 6 coastal districts and 1 inland district showed very low prevalence rates, well below the 20% deemed necessary for a mass drug administration [16].

References

13. PAHO. Epidemiological profiles of neglected diseases and other infections related to poverty in Latin America and the Caribbean. (2009).